The global spine biologics market is projected to grow at a 3.5 percent compound annual growth rate to reach $2.72 billion by the end of 2025, according to a Market Reports World report.
Biologics
Grand Junction, Colo.-based Vail-Summit Orthopaedics & Neurosurgery is using injectable plasma and stem cells to treat sports-related ligament and tendon injuries, according to an article written by William Sterett, MD, in Summit Daily.
Regenerative medicine company Osiris Therapeutics named Samson Tom as president and CEO.
SpinalCyte received FDA Investigational New Drug clearance for CybroCell, its fibroblast-based therapy to treat degenerative disc disease.
Researchers implanted tissue-engineered spinal discs in a goat model which provided long-term function, according to a study in Science Translational Medicine.
Advertisement
Stability Biologics provides allograft products for spine, orthopedic and wound care applications.
Researchers have developed a composite double-network hydrogel that adheres to soft tissues such as cartilage and the meniscus, according to an article in ACS Applied Materials & Interfaces.
SurGenTec completed the initial clinical launch of its new GraftGun bone graft delivery system combined with Aziyo Biologics’ ViBone Viable Bone Matrix prefilled tubes for minimally invasive spine surgery.
ORTHOReBIRTH USA and Altamonte Springs, Fla.-based Adventist Health System Sunbelt Healthcare Corp. entered into a product agreement.
Spinal device company Innovasis partnered with Stability Biologics to enter the biologics market.